Thank you for the question. Here is the plain text representation of the document:

Smoking-related general and cause-specific mortality in Estonia

Gea Kõks, Krista Fischer and Sulev Kõks

Abstract

Background: Tobacco smoking is known to be the single largest cause of premature death worldwide. The aim of present study was to analyse the effect of smoking on general and cause-specific mortality in the Estonian population.

Methods: The data from 51,756 adults in the Estonian Genome Center of the University of Tartu was used. Information on dates and causes of death was retrieved from the National Causes of Death Registry. Smoking status, general survival, general mortality and cause-specific mortality were analysed using Kaplan-Meier estimator and Cox proportional hazards models.

Results: The study found that smoking reduces median survival in men by 11.4 years and in women by 5.8 years. Tobacco smoking produces a very specific pattern in the cause of deaths, significantly increasing the risks for different cancers and cardiovascular diseases as causes of death for men and women. This study also identified that external causes, such as alcohol intoxication and intentional self-harm, are more prevalent causes of death among smokers than non-smokers. Additionally, smoking cessation was found to reverse the increased risks for premature mortality.

Conclusions: Tobacco smoking remains the major cause for losses of life inducing cancers and cardiovascular diseases. In addition to the common diseases, external causes also reduce substantially the years of life. External causes of death indicate that smoking has a long-term influence on the behaviour of smokers, provoking self-destructive behaviour. Our study supports the idea, that tobacco smoking generates complex harm to our health increasing mortality from both somatic and mental disorders.

Keywords: Smoking, Survival, Cause of death, Cancer, Mortality

Background

Tobacco smoking is a single major cause of premature death worldwide [1, 2]. Despite substantial reduction in the use of tobacco, smoking still causes more deaths globally than diseases like tuberculosis, HIV and malaria combined, making it the largest preventable health risk factor [3, 4]. The use of tobacco is legally allowed and therefore the prevalence of smoking behaviour is still very high. While in the developed countries tobacco use is reduced and restricted, in developing countries the tobacco epidemic is still in the growing phase [1, 5]. It has been estimated that tobacco smoking causes globally 6 million deaths in a year [6]. 80% of these deaths are premature and affect lower income individuals [5]. This all makes tobacco smoking the largest single avoidable cause for mortality. Reducing the prevalence of smoking increases the health of the general population by avoiding premature disability and death. Smoking cessation and support to stop smoking are the easiest tools to improve the quality of life in population [7, 8].

While it is clear that smoking increases mortality, the association between smoking and mortality is different across specific causes of death. Cancers, chronic obstructive diseases of respiratory system and cardiovascular diseases are the most commonly referred smoking-induced causes of death.

The association between smoking and lung cancer has been described already in 1950 and following years [9–12]. Later studies found clear association with other cancers as well [13]. Tobacco smoking is known to cause cancers of upper gastrointestinal tract, pancreas, prostate [14]. While
the association is conclusive for lung and upper respiratory tract cancers, the connection between smoking and other cancers does not have conclusive evidence.

Tobacco smoking is reported to cause 90% of all chronic obstructive pulmonary disease (COPD) mortality and smoking cessation is the best measure to avoid this outcome [15]. The relative risk for smokers to die from COPD is 25.6 in men and 22.3 in women, compared to non-smokers [16]. Therefore, one of the most common health problems in smokers is COPD [16, 17]. The development of COPD is dependent on the chronic persistent inflammation in the lung tissue that induces tissue-remodelling [18]. COPD is the most common and the most prevalent disease in smokers and smokers have very highly increased risk for COPD.

Cardiovascular diseases have been found to be the third major cause of death caused by smoking [16, 19]. The main causes for death are ischaemic heart disease, cerebrovascular disease and other heart diseases [16]. Interestingly the risks caused by smoking of death due coronary heart disease are remarkably different between men and women [20]. Women who smoke have four times increased risk of death from ischaemic heart disease, while male smokers only have twofold increased risk [20]. For cerebrovascular diseases, this sex difference in risk has not been found [21]. This influence of sex on the risk of ischaemic heart disease is striking and its mechanism could be biological or behavioural.

Increased prevalence of chronic diseases suggests increased inflammatory activity in smokers. Indeed, several studies indicate chronic inflammation in the smokers and different immunomodulating toxins in the smoke probably cause increased immune reactivity [22, 23]. A recent study analysed RNA expression profiles in the blood of smokers and non-smokers and identified a highly significant increase in the expression of GPR15 gene [24]. GPR15 is an orphan receptor that is responsible for the homing of tissue-specific immune cells [25].

Several previous studies have shown that the association between smoking with different causes of deaths is variable [26]. There are some large-scale population studies where causes of death and association with smoking have been addressed [7, 13, 16]. However, more detailed differential risk analyses for smoking and causes of death are not that common [27]. The goal of present study was to analyse the smoking-caused mortality in the Estonian Genome Center cohort and to describe the differential sensitivity for the different specific causes of death.

Methods
The aim, design and setting of the study
The aim of the study was to analyse smoking-induced mortality profile in Estonia using data at the Estonian Genome Center. Estonian Genome Center at the University of Tartu is a population-based biobank that recruited a cohort of 51,756 participants, including adults from all counties in Estonia, accounting for approximately 5% of the Estonian adult population during the recruitment period. Recruitment was performed during the period from 2002 to 2012 [28]. At baseline, an extensive phenotype questionnaire was conducted together with a measurement panel. Follow-up data is available from linkage with national health-related registries and the Estonian Health Insurance database. Mortality information was retrieved from the Estonian Causes of Death Registry and last retrieval was performed in September 2015.

The Ethics Review Committee on Human Research of the University of Tartu approved the protocols and informed-consent forms used in this study. All of the participants signed a written informed-consent form.

Smoking data
Smoking data were collected during the recruitment of donors to the Estonian Genome Center. The following questions were asked:

1) “If you have ever smoked regularly, when did you start?”
2) “How many of the tobacco products have you used during the last 12 months?”
3) “For how many years have you used tobacco products with this amount?”
4) “What is the amount of tobacco products you used most commonly?”
5) “For how many years have you used tobacco products as described?”

Smoking behaviour was divided into three major categories: current smokers, former smokers and never smoked. Former smokers were individuals who had not smoked for at least one year prior to recruitment.

Statistical analysis
All statistical analyses were stratified by sex, as previous analysis indicated significant differences in the smoking patterns between males and females. Statistical analysis was performed in R studio and packages “survival”, “epitools”, “Publish”, “dplyr” were used. Survival data were modelled by using Cox model [29]. Survival was calculated from the date when subjects joined the Estonian Genome Centre cohort (2002–2012) and censored at date of death, retrieved from the National Death Registry, or September 2015, whichever came first.

The data on smoking status, smoking intensity and smoking pattern was categorized (current, former and never smokers; smoking up to 10, 10–20 or more than...
20 cigarettes per day; up to 20 years or more than 20 years of smoking history) and tabulated by four age
groups (18–25, 26–45, 46–65 and more than 65 years).
Mortality data was tabulated according to the cause of
death, smoking status and sex of all participants. For
survival analysis, the Kaplan-Meier estimator was used
to plot survival curves. Starting time-point was the date
when subjects joined the Estonian Genome Centre
cohort and the end-point was the date of data retrieval
from the National Death Registry. Cox proportional
hazards regression analysis was used to calculate hazard
ratio for all-cause mortality and cause-specific mortality,
comparing current and former smokers with never-
smokers, using age as a time scale (to account for left-
truncation in the data). Cox regression was also used to
estimate the effects of smoking intensity (cigarettes per
day) and length of smoking history on overall survival.
Using the Kaplan-Meier method for left-truncated data,
the median survival time for current, former and never
smokers in the cohort also was estimated with a 95%
confidence interval.

For cause-specific mortality, the causes of death
according to the 10th Revision of International Statistical
Classification of Diseases and Related Health Problems
(ICD-10) were analysed separately in men and women.

Results
General smoking characteristics in the cohort
The Estonian Genome Center includes 51,756 partici-
pants: 17,777 men and 33,979 women (Table 1), aged 18
and over at recruitment. The recruitment period was
between 2002 and 2012.

Basic demographic information and smoking charac-
teristics are given in the Tables 2 and 3. Of all 17,777
men (Table 2), 39.4% were never-smokers, 20.8% former
and 39.8% current smokers. Of all 33,979 women
(Table 3), 67.3% were never-smokers, 10.0% former
and 22.7% current smokers. This indicates clearly
prevalence in Estonian men is 41.2% and in women
24.9% [1].

According to the recent WHO data, the smoking
prevalence in Estonian men is 41.2% and in women
24.9% [1].

The average age to start smoking in men was 18 (SD
4.2) years and in women 21 (SD 6.3) years. Analysis of
the different age groups indicated that nowadays people
start smoking at a younger age than in the past. Men in
the age group 65+ had started smoking at age 20 and
women at age 27 in the average. On the other hand,
average age of starting to smoke in the youngest age
group (18–25) was 16 for both, men and women.

The cohort was divided into two groups according to
the duration of smoking – up to 20 years and over
20 years of smoking. In the study cohort, most of the
smokers were smoking for less than 20 years. This trend
also was valid in all subgroups of the cohort.

The number of cigarettes per day differed significantly
between male and female smokers. On average, men
smoked 15 (SD 9) and women smoked 9 (SD 7) ciga-
rettes per day. The average number of cigarettes per day
was similar in current and former smokers.

All-cause mortality
By September 2015, 3364 (1649 men and 1715 women)
people the cohort had died. The average age at death
was 69 (SD 14) and 74 (SD 14) years for men and
women, respectively. A general description of the more
frequent causes of death and their association with
smoking is given in the Table 4.

The Kaplan-Meier curves for overall survival were sig-
nificantly different in current, former and never
smokers, in both men and women (Fig. 1). The test for
survival curve differences in men between three different
smoking categories (“Never”, “Former”, “Current”) was
highly significant ($p = 1.8*10^{-40}$). In case of women,
the difference was also highly significant ($p = 1.3*10^{-14}$)
for three-group comparison. The never smoked group had
the longest survival and current smokers had the short-
est survival. Survival of former smokers was in-between
the never and current smokers indicating beneficial
effect of quitting.

Age-adjusted Cox regression of all-cause mortality in
both sexes indicated significantly increased hazard ratio
(HR) and 95% confidence interval (CI), for current 3.1
(CI 2.8–3.4) and former 1.6 (CI 1.5–1.8) smokers, com-
pared to never smokers. When different sexes were ana-
lysed separately, almost similar results were seen. In
male current smokers HR was 2.5 (CI 2.2–2.8) and in
former smokers 1.3 (CI 1.2–1.5) for all-cause mortality.
Currently smoking women had HR 2.6 (CI 2.2–3.0) and
former smokers had 1.3 (CI 1.1–1.5) for all-cause mor-
tality. Taken together, smoking status was significantly
associated with increased all-cause mortality and this
association was similar for men and women.

### Table 1 Age distribution in the cohort of the Estonian Genome Center of the University of Tartu 2002–2012

| Age group | Men | | Women | | Total | |
|-----------|-----|-----|--------|-----|-----|-----|
| n         | %   | n   | %      | n   | %   | n   | %   |
| 18–25     | 3896 | 7.5 | 5302 | 10.3 | 9198 | 17.8 |
| 26–45     | 6016 | 11.6 | 12,436 | 24.0 | 18,452 | 35.6 |
| 46–65     | 5292 | 10.2 | 11,257 | 21.8 | 16,549 | 32.0 |
| over 65   | 2573 | 5.0 | 4984 | 9.6 | 7557 | 14.6 |
| Total     | 17,777 | 34.3 | 33,979 | 66.7 | 51,756 | 100.0 |
Median age at death and loss of life years

Smoking significantly reduced median age of death. In the entire study group, median age of death in never smokers was 85.7 (CI 85.4—86.2), in former smokers 80.6 (CI 79.6—81.6) and in current smokers 74.7 (CI 73.5—75.7) years.

The median age of death for men who never smoked was 82.6 (CI 81.4—83.6), for former smokers 78.4 (CI 77.1—79.4) and for current smokers 71.2 (CI 70.2—72.3) years. Median age of death for women who never smoked was 86.4 (CI 86.1—86.8), for former smokers 85.8 (CI 83.4—88.1) and for current smokers 80.6 (CI 77.9—81.8) years.

Therefore, we estimate that the median loss of life years in smoking men is 11.4 years and in women 5.8 years at lost. In the case of men, former smokers lived significantly longer than current smokers, but significantly less than never smokers. In the case of women, the difference in age of death of former and never smokers were very small.

Effect of smoking duration and smoking intensity on all-cause mortality

The increased risk for all-cause mortality was also significantly associated with smoking duration. Men who smoked more than 20 years had HR 2.1 (CI 1.9—2.3) and men who smoked less than 20 years had HR 2.3 (CI 2.1—2.5). Women with smoking duration more than 20 years had HR 2.7 (CI 2.4—3.1) and with less than 20 years had HR 1.4 (CI 1.3—1.6). However, the number of cigarettes per day had a less severe influence on the all-cause mortality than smoking duration.

Cause-specific mortality

The subsequent analysis involved specific causes for mortality. The study cohort altogether had 272 unique ICD-10 main categories as cause of death. The most frequent causes of death (more than 100 cases) were chronic ischaemic heart disease (I25), hypertensive heart disease (I11), malignant neoplasm of bronchus and lung
and cerebral infarction (I63) across the entire cohort (Table 4). Men and women also were analysed separately and for specific causes of death age-adjusted hazard ratio was calculated with non-smokers as reference. Statistically significant findings are shown in Tables 5 and 6.

The most significant specific causes for mortality in currently smoking men were malignant neoplasm of bronchus and lung (C34, HR 32.9), heart failure (I50, HR 24.4), chronic obstructive pulmonary disease (J44, HR 23.1) and subsequent myocardial infarction (I22, HR 9.4) (Table 5, Fig. 2). Current smokers also had a significantly increased hazard ratio to die from malignant neoplasms at unspecified sites (C80, HR 7.8). Interestingly, current smokers also had a significantly elevated hazard ratio for accidental poisoning by an exposure to alcohol (X45, HR 3.6), for cerebral infarction (I63, HR 3.3), for hypertensive heart disease (I11, HR 2.1) and chronic ischaemic disease (I25, HR 1.9) as causes of death.

Compared to current smokers, former male smokers (Table 5) had significantly lower hazard ratio values for most of the causes of death. This finding illustrates a clear health benefit of quitting smoking as the general risk for death reduced from 2.5 to 1.3 and the number of specific causes for death decreased. In men who stopped smoking, only four causes of death remained statistically significant compared to those who have never smoked. These causes of death were chronic obstructive pulmonary disease (J44, HR 9.7), malignant neoplasm of bronchus and lung (C34, HR 9.2), subsequent myocardial infarction (I22, HR 5.4) and cerebral infarction (I63, HR 2.7).

In the case of currently smoking women (Table 6, Fig. 3) the highest hazard ratio as a cause of death were for chronic obstructive pulmonary disease (J44, HR 19.3), for malignant neoplasm of bronchus and lung (C34, HR 19.2), heart failure (I50, HR 19.7), chronic obstructive pulmonary disease (J44, HR 19.0), and subsequent myocardial infarction (I22, HR 15.5).
Table 4  Basic characteristics of smoking, number of all causes of death and the most common cause-specific deaths in the studied cohort

| Variable                                           | Men                      | Women                   |
|----------------------------------------------------|--------------------------|-------------------------|
|                                                    | Current | Former | Never | Current | Former | Never |
| Persons in cohort                                  | 7068    | 3698   | 7011  | 7722    | 3402   | 22,855 |
| All causes death in cohort                         | 627     | 548    | 474   | 270     | 147    | 1298   |
| C16 Malignant neoplasm of stomach                  | 8       | 13     | 10    | 10      | 5      | 34     |
| C18 Malignant neoplasm of colon                    | 3       | 10     | 9     | 4       | 1      | 25     |
| C25 Malignant neoplasm of pancreas                 | 11      | 18     | 11    | 12      | 6      | 32     |
| C34 Malignant neoplasm of bronchus and lung        | 73      | 42     | 5     | 15      | 6      | 19     |
| C50 Malignant neoplasm of breast                   | –       | –      | –     | 12      | 8      | 35     |
| C56 Malignant neoplasm of ovary                    | –       | –      | –     | 5       | 8      | 25     |
| C61 Malignant neoplasm of prostate                 | 16      | 17     | 29    | –       | –      | –      |
| C80 Malignant neoplasm without specification of site | 9   | –      | 2     | 4       | –      | 9      |
| I11 Hypertensive heart disease                     | 41      | 41     | 39    | 20      | 22     | 190    |
| I13 Hypertensive heart and renal disease           | 8       | 10     | 13    | 5       | 4      | 28     |
| I21 Acute myocardial infarction                    | 16      | 11     | 12    | 6       | 4      | 31     |
| I22 Subsequent myocardial infarction               | 12      | 9      | 2     | 2       | 2      | 11     |
| I25 Chronic ischaemic heart disease                | 80      | 113    | 100   | 21      | 21     | 243    |
| I35 Nonrheumatic aortic valve disorders            | 5       | 2      | 6     | 1       | 1      | 17     |
| I42 Cardiomyopathy                                 | 16      | 9      | 12    | 5       | 2      | 11     |
| I50 Heart failure                                  | 10      | 2      | 1     | 4       | 1      | 17     |
| I63 Cerebral infarction                            | 16      | 30     | 13    | 9       | 9      | 79     |
| I70 Atherosclerosis                                | 2       | 3      | 5     | 2       | 1      | 11     |
| J15 Bacterial pneumonia                           | 1       | 4      | 3     | 3       | 2      | 7      |
| J44 Chronic obstructive pulmonary disease          | 17      | 18     | 2     | 7       | 1      | 10     |
| K70 Alcoholic liver disease                        | 8       | 7      | 6     | 7       | 0      | 2      |
| R99 Ill-defined and unspecified causes of mortality | 6   | 3      | 4     | 5       | 0      | 2      |
| X45 Accidental poisoning by and exposure to alcohol | 14 | 1      | 3     | 2       | 0      | 1      |
| X70 Intentional self-harm by hanging, strangulation and suffocation | 13 | 3      | 8     | 5       | 1      | 5      |

Fig. 1  Kaplan-Meier survival probabilities for current and former smokers and for men and women who have never smoked. Reduced survival of the smokers is evident
alcoholic liver disease (K70, HR 13.9), for heart failure (I50, HR 10.3) and for atherosclerosis (I70, HR 10.2). Current smokers also had increased hazard ratio for ill-defined and unspecified causes of mortality (R99, HR 8.5), for malignant neoplasm of bronchus and lung (C34, HR 6.7), for bacterial pneumonia (J15, HR 6.4), for acute myocardial infarction (I21, HR 4.7) and intentional self-harm by hanging, strangulation and suffocation (X70, HR 4.6) as a cause of death. In currently smoking women, the hazard ratio for accidental poisoning by an exposure to alcohol

| Variable | ICD-10 code for cause of death | Current smokers | Former smokers |
|----------|--------------------------------|-----------------|----------------|
| C34      | Malignant neoplasm of bronchus and lung | 32.9 | 13.2–82.0 | 2.1 |
| C80      | Malignant neoplasm without specification of site | 7.8 | 1.5–39.5 | – |
| C16–C80  | Malignant neoplasms | 4.0 | 2.1–5.4 | 1.7 |
| I11      | Hypertensive heart disease | 2.1 | 1.3–3.3 | 1.2 |
| I22      | Subsequent myocardial infarction | 9.4 | 2.0–43.3 | 5.4 |
| I25      | Chronic ischaemic heart disease | 1.9 | 1.4–2.6 | 1.3 |
| I50      | Heart failure | 24.4 | 2.8–213.1 | 2.1 |
| I63      | Cerebral infarction | 3.3 | 1.5–7.0 | 2.7 |
| I00–I99  | Diseases of the circulatory system | 2.6 | 1.8–2.7 | 1.3 |
| J44      | Chronic obstructive pulmonary disease | 23.1 | 5.2–101.8 | 9.7 |
| J00–J99  | Diseases of the respiratory system | 7.8 | 3.2–18.7 | 4.2 |
| X45      | Accidental poisoning by and exposure to alcohol | 3.6 | 1.1–12.7 | 0.5 |
| V01–Y98  | External causes of morbidity and mortality | 2.2 | 1.5–3.3 | 0.8 |

| Variable | ICD-10 code for cause of death | Current smokers | Former smokers |
|----------|--------------------------------|-----------------|----------------|
| C25      | Malignant neoplasm of pancreas | 4.0 | 1.9–8.3 | 1.9 |
| C34      | Malignant neoplasm of bronchus and lung | 6.7 | 3.2–14.4 | 3.0 |
| C56      | Malignant neoplasm of ovary | 0.9 | 0.3–2.5 | 2.4 |
| C16–C80  | Malignant neoplasms | 2.7 | 1.9–3.7 | 1.8 |
| I11      | Hypertensive heart disease | 2.2 | 1.3–3.6 | 1.4 |
| I13      | Hypertensive heart and renal disease | 3.3 | 1.1–9.8 | 1.7 |
| I21      | Acute myocardial infarction | 4.7 | 1.9–12.2 | 1.6 |
| I25      | Chronic ischaemic heart disease | 2.1 | 1.3–3.3 | 1.1 |
| I50      | Heart failure | 10.3 | 2.9–38.3 | 0.9 |
| I63      | Cerebral infarction | 3.4 | 1.6–7.0 | 1.6 |
| I70      | Atherosclerosis | 10.2 | 1.8–57.4 | 1.2 |
| I00–I99  | Diseases of the circulatory system | 2.7 | 2.1–3.5 | 1.3 |
| J15      | Bacterial pneumonia | 6.4 | 1.3–32.2 | 3.2 |
| J44      | Chronic obstructive pulmonary disease | 19.3 | 7.1–52.6 | 1.3 |
| J00–J99  | Diseases of the respiratory system | 12.0 | 5.3–27.3 | 1.8 |
| K70      | Alcoholic liver disease | 13.9 | 2.6–75.8 | – |
| R99      | Ill-defined and unspecified causes of mortality | 8.5 | 1.6–45.6 | – |
| X70      | Intentional self-harm by hanging, strangulation and suffocation | 4.6 | 1.2–18.1 | 1.6 |
| V01–Y98  | External causes of morbidity and mortality | 7.6 | 3.9–14.7 | 2.6 |
(X45) was elevated, but this increase did not reach statistical significance.

Smoking cessation significantly reduced the risks for specific causes of death and most of the hazard ratios were not different compared to the never smoked group (Table 6). In former smokers only malignant neoplasm of the bronchus and lung (C34, HR 3.0) and malignant neoplasm of the ovaries (C56, HR 2.4) remained significant specific causes of death.

Taken together, current smokers have significantly increased mortality and a specific pattern of cause of death. Respiratory and cardiovascular diseases were the most significant causes of death. This indicates, that smoking does the most harm to the lungs and cardiovascular system. The former smokers group had significantly less mortality than current smokers and therefore, smoking cessation significantly reduces the hazard ratio for cause-specific mortality. Former smokers still have significantly increased hazard to die from the lung diseases.

Discussion

Based on the epidemiological analysis of tobacco smoking in the cohort of the Estonian Genome Center, this study concluded that Estonia still belongs to the group of countries with high number of smokers. On average, there are two times more smokers in Estonia than in Western-European countries. The high number of smokers also is characteristic for other Eastern-European countries. This statement is particularly true in men. In Estonia and other Eastern-European countries around 40% of men are smokers, whereas in Western-European countries only 10–20% of men are smokers. In the case of female smokers, Estonia is similar to Western-European countries, where 20% of women smoke [1]. This fits the typical epidemiologic pattern seen in Europe and developed countries. Differences between different countries are smaller in case of women and are prominent in the case of men. These differences also explain the significantly worse health of men in Eastern-European countries. Men smoke too much and they pay for that with their health and quality of life as seen by the reduced life span.

The smoking prevalence in the Estonian Genome Center cohort is similar to the prevalence described in other study based on general population in three Baltic states [30]. In addition, the age-group prevalence of the Estonian Genome Center cohort is similar to the general Estonian population [28]. Therefore, our results are generalizable for the entire Estonian population.

While the proportion of smokers in Estonia has been stable for 20 years, the age at which individuals start smoking tobacco has decreased remarkably. At present, people start to smoke at the median age of 16 and this is similar for men and women. This trend is worrisome and has an important impact on the health of the Estonian population.

The age-group analysis indicated that men start to quit smoking at the age 46–65, women start quitting 26–45. This indicates that women smoke for a shorter period of their life. Taken together, men start smoking earlier, they
smoke more cigarettes per day (mostly 20 cigarettes per day) and they quit smoking later. At the same time, women smoke less (mostly 10 cigarettes per day) they start smoking later and give up smoking earlier. This difference could also be detectable as the difference in survival and causes of death. Therefore smoking has a significantly larger impact on men's health than in women.

There present study analysed the impact of tobacco smoking on the hazard of all-cause and cause-specific mortality. Survival analysis clearly indicated shorter median survival in smokers compared to non-smokers. Survival analysis also indicated that smoking cessation is beneficial for the survival. This means that toxic effects of smoking are reversible. The positive effect of quitting on the survival has been described in many previous studies [16, 17, 19].

Interestingly, in women the general survival differences caused by tobacco smoking were less prominent. For example, men who smoked lived on average 11.4 years less than non-smokers, but women who smoked only lost 5.8 years on average. In some previous studies, similar sex-differences in smoking effects have been found [31]. This sex-difference may be explained by the lower smoking activity in women. In our sample women smoked 9 cigarettes per day while men smoked 15 cigarettes per day on average. Women also start smoking later and quit earlier that makes their smoking duration shorter and this explains the reduced number of cigarettes smoked by women. Previous studies support this idea. If women smoke more they have mortality and morbidity profile similar to men and the sex differences disappear [32, 33].

The loss of years found from the survival analysis in the present study was similar to the findings from previous studies where loss of at least 10 years was found [17]. This indicates that the study design used and the results are comparable with other studies. For example, the study of Jha et al. analysed survival from the age 25 [17]. The present study included people from the age 18 and mortality data were retrieved from the National Death Registry. This approach has been used for many previous studies.

The impact of smoking duration on general mortality gave somewhat controversial results as in men we found increased mortality in both groups compared to non-smokers. In case of men, the difference in general mortality between smoking more than 20 years and less than 20 years was very small (HR 2.1 versus 2.3) and statistically not significant. In case of women, the difference related to smoking duration was significant. Women smoking more than 20 years had HR 2.7 (CI 2.4–3.1) and women smoking less than 20 years have HR 1.4 (CI 1.3–1.6). This finding is similar to the previously published findings [34]. Similarly, we found that number of cigarettes per day does not have impact on the all-cause mortality.

The cause-specific analysis of death should describe the most common reasons why smokers lose years of their life. The comparison of causes of death induced by smoking in men and women identified very high similarities between both sexes in the pattern of cause of death. Namely, the most significantly smoking-associated causes of death were diseases of the respiratory and cardiovascular systems both in men and women. This indicates that there is a common biological mechanism behind the smoking that increases morbidity and mortality. This mechanism is the same in men and women. One very good candidate for this common pathway is the GPR15 that was recently found to be upregulated in both male and female smokers [24].

In addition to the lung and heart diseases, the one of the largest hazard ratio was related to external causes of death. In men, this cause was death from accidental poisoning by an exposure to alcohol (X45). In women, these causes were alcoholic liver disease (K70) and intentional self-harm by hanging, strangulation, suffocation (X70). Alcoholic liver disease (K70) is closely related to a poisoning by an exposure to alcohol (X45) and should be taken as an external cause of disease. The significantly increased risks for external causes of death have been described in few previous studies and more detailed analysis is difficult to find [14]. The prevalence of alcohol poisoning and self-harm in former smokers as causes of death were the same in former smoker and non-smokers. This means that the increased incidence of suicide and alcohol intoxication in current smokers could reflect particular biologically determined behavioural endophentotype and personality characteristics of current smokers. Smokers could be more impulsive or more prone to risk taking. One side of this behaviour is increased alcohol consumption, binge drinking and suicide. Not many studies indicate causes for this kind of association, but most probably there is common genetic variation between smokers and suicide victims. One recent study found an association between the polymorphic variable number tandem repeat (VNTR) in the SLC6A4 gene and increased risk for tobacco use disorder [35]. The association between polymorphisms in the BDNF gene and nicotine dependence also has been described [36]. Moreover, as tobacco smoking behaviour is often explained in conjunction with mood disorders, the link between suicide and smoking is not that surprising. At least one deletion in the GSTM1 and GSTT1 genes has been described in anxious smokers while no association with mood disorders have been found [37].

One of the limitations of the study is the small number of several specific causes of death that could make our analysis imprecise. This small number is caused by the
short time for observation. Currently it is impossible to get better estimations and this study can be a starting point for the repeated mortality analysis of the Estonian Genome Center cohort. Extended observation will eventually increase the number of specific causes and improve the precision of the analysis. In order to improve the regression analysis, we merged some cases (like J44, J45 and J47) that increased the power to estimate proportional hazard for smokers and ex-smokers. This helped to get more reliable HR estimations.

**Conclusions**

In conclusion, the prevalence of tobacco smoking is still high in Estonia and men smoke at least two times more than women. This high prevalence is reflected in substantial loss of years of life and shorter survival of men. Smoking cessation can reverse the increased mortality, but the time needed for this reversal is not known. The two main types of cause of death in smokers were diseases of lung and cardiovascular system. The third group of cause of death is self-destructive behaviour. This finding suggests a common biological substrate in the brain of nicotine addicts and risk-taking behaviour. Better knowledge about the link between psychiatric illnesses and smoking could help to develop more effective interventions. Further studies are required to understand the genetic and biological background of this association.

**Acknowledgements**

The friendly support from the staff of Estonian Genome Centre is acknowledged. Financial support from Estonian Ministry of Education and Research (institutional research grants IUT20–46 and IUT20–60 of the), from the European Commission (H2020 programme grants 668989 Transgeno and 692145 ePerMed) and from the European Regional Development Fund (project no. 2014–2020.4.01.15-0012, Gertransmed) are acknowledged.

**Funding**

GK was supported by Estonian Research Agency grant IUT20–46 and by the H2020 ERA-chair grant (agreement 668,089, project Transgeno); KF was supported by Estonian Research Agency grant IUT20–60 and by the H2020 project ePerMed (grant no. 692145); SK was supported by Estonian Research Agency grant IUT20–46 and by the H2020 ERA-chair grant (agreement 668,089, project Transgeno).

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

GK performed the statistical analysis, arranged ethical approvals, prepared figures and drafted the manuscript; KF provide statistical analysis advice, commented on the manuscript and figures; SK conceived the study, helped with data management and helped to finalize the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The Ethics Review Committee on Human Research of the University of Tartu approved the protocols and informed-consent forms used in this study. All of the participants signed a written informed-consent form.

**Consent for publication**

Not applicable.

**Competing interests**

Authors declare that they do not have any competing interests regarding to the present manuscript and funding.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Pathophysiology, University of Tartu, 19 Ravila Street, 50411 Tartu, Estonia. 2. Estonian Genome Center, University of Tartu, 23b Riaa Street, 51010 Tartu, Estonia. 3. Department of Reproductive Biology, Estonian University of Life Sciences, 62 Kreutzwaldi Street, 51006 Tartu, Estonia.

**Received:** 2 March 2017 **Accepted:** 12 July 2017

**Published online:** 19 July 2017

**References**

1. WHO: MPOWER: a policy package to reverse the tobacco epidemic. In: Geneva; 2011.

2. Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer. 2009;9(9):655–64.

3. Oberg M, Jaakkola MS, Woodward A, Peruga A, Pruss-Ustun A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet. 2011;377(9760):139–46.

4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.

5. WHO: WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco. In: Geneva: World Health Organization; 2011.

6. WHO: WHO report on the global tobacco epidemic, 2013: warning about the dangers of tobacco. In: Geneva: World Health Organization; 2013.

7. Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet. 2013;381(9861):133–41.

8. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321(7257):232–9.

9. Doll R, Hill AB. Smoking and carcinoma of the lung: preliminary report. Br Med J. 1950;2(4682):739–48.

10. Doll R, Hill AB. A study of the aetiology of carcinoma of the lung. Br Med J. 1952;2(4797):1271–86.

11. Doll R, Hill AB. A study of the aetiology of carcinoma of the lung. Pakistan journal of health. 1953;3(2):65–94.

12. Doll R. Smoking and carcinoma of the lung. Acta-Unio Internationalis Contra Cancrum. 1953;9(3):495–506.

13. Doll R, Peto R, Boenham J, Sutherland I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer. 2005;92(3):426–9.

14. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ. 1994;309(6959):901–11.

15. Tashkin DP, Murray RP. Smoking cessation in chronic obstructive pulmonary disease. Respir Med. 2009;103(7):963–73.

16. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, Hartge P, Gapsuc SM. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351–64.

17. Jha P, Ramusundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, McAlpine F, Petos R. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341–50.

18. Sohal SS, Ward C, Danial W, Wood-Baker R, Walters EH. Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease. Expert review of respiratory medicine. 2013;7(3):275–88.

19. Thun MJ, Day-Lally CA, Calle EE, Flanders WD, Heath CW Jr. Excess mortality among cigarette smokers: changes in a 20-year interval. Am J Public Health. 1995;85(9):1223–30.

20. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011;378(9799):1297–305.

21. Peters SA, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81
cohorts, including 3,980,359 individuals and 42,401 strokes. Stroke. 2013;44(10):2821–8.
22. Rom O, Avezov K, Aizenbud D, Reznick AZ. Cigarette smoking and inflammation revisited. Respir Physiol Neurobiol. 2013;187(1):5–10.
23. Lee J, Taneja V, Vascallo R. Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res. 2012;91(2):142–9.
24. Koks G, Uudelepp ML, Limbach M, Peterson P, Reimann E, Koks S. Smoking-induced expression of the GPR15 gene indicates its potential role in chronic inflammatory pathologies. Am J Pathol. 2015;185(11):2898–906.
25. Kim SW, Xiang WW, Kwak C, Yang Y, Lin XW, Ota M, Sarpel U, Rifkin DB, Xu R, Littman DR. GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science. 2013;340(6139):1456–9.
26. Kenfield SA, Wei EK, Rosner BA, Glynn RJ, Stampfer MJ, Colditz GA. Burden of smoking on cause-specific mortality: application to the Nurses’ health study. Tob Control. 2010;19(3):248–54.
27. Taghizadeh N, Vonk JM, Boezen HM. Lifetime smoking history and cause-specific mortality in a cohort study with 43 years of follow-up. PLoS One. 2016;11(4):e0153310.
28. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alaveere H, Snieder H, Perola M, Ng PC, Magi R, Milani L, et al. Cohort profile: Estonian biobank of the Estonian genome center, University of Tartu. Int J Epidemiol. 2014;
29. Therneau TM, Grambsch PM. Modeling survival data: extending the cox model, vol. statistics for biology and health. New York: Springer; 2000.
30. Pizzo de Castro MR, Guembarovski RL, Ariza CB, Reiche EM, Vargas HO, Vargas MM, de Melo LG, Dodd S, Berk M, et al. SLC6A4 STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: a case control study. BMC Genet. 2014;15:78.
31. Jamal M, Van der Does W, Elzinga BM, Molendijk ML, Penninx BW. Association between smoking, nicotine dependence, and BDNF Val66Met polymorphism with BDNF concentrations in serum. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco. 2015;17(3):323–9.
32. Odebrecht Vargas Nunes S, Pizzo de Castro MR, Ehara Watanabe MA, Losi Guembarovski R, Odebrecht Vargas H, Reiche EM, Kaninami Morimoto H, Dodd S, Berk M. Genetic polymorphisms in glutathione-S-transferases are associated with anxiety and mood disorders in nicotine dependence. Psychiatric genetics. 2014;24(3):87–93.